Modulation of transcriptomic signature of the infected host: a new therapeutic strategy for the management of severe viral infections? Example of the flu;La modulation de la signature transcriptomique de l’hôte infecté : une nouvelle stratégie thérapeutique dans les viroses graves ? Exemple de la grippe

Reanimation

Volumn 25, Issue , 2016, Pages 53-61

  Poissy, J ^a,b   Terrier, O ^c   Lina, B ^c,d   Textoris, J ^e,f   Rosa Calatrava, M ^c  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f University of Lyon EA 7426 Pathophysiology of Injury Induced Immunosuppression PI3   (France)

Author keywords

Drug repurposing; Flu; Transcriptome; Viral infections

Indexed keywords

EID: 84964757083     PISSN: 16240693     EISSN: 19516959     Source Type: Journal    
DOI: 10.1007/s13546-016-1188-1     Document Type: Article

References (62)

1. Taylor LH, Latham SM, Woolhouse ME (2001) Risk factors for human disease emergence. Philos Trans R Soc Lond B Biol Sci 356: 983–9
2. Woolhouse M, Gaunt E (2007) Ecological origins of novel human pathogens. Critical reviews in microbiology 33: 231–42
3. Woolhouse ME, Howey R, Gaunt E, et al (2008) Temporal trends in the discovery of human viruses. Proc Biol Sci 275: 2111–5
4. Cheng VC, Lau SK, Woo PC, et al (2007) Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clinical Microbiol Rev 20: 660–94
5. Zumla A, Hui DS, Perlman S (2015) Middle East respiratory syndrome. Lancet 386: 995–1007
6. Legand A, Briand S, Shindo N, et al (2013) Addressing the public health burden of respiratory viruses: the battle against respiratory viruses (BRaVe) initiative. Future Virol 8: 953–68
7. Jain S, Self WH, Wunderink RG, et al (2015) Communityacquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373: 415–27
8. Pavia AT (2011) Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis 52:S284–S9
9. Shaw ML, Palese P (2006) Orthomyxoviridae. In: Knipe DM, Howley PM (eds) Fields Virol. Lippincott Williams & Wilkins, Philadelphia, USA, pp 1151–85
10. Hutchinson EC, von Kirchbach JC, Gog JR, et al (2010) Genome packaging in influenza A virus. J Gen Virol 91: 313–28
11. Zimmer SM, Burke DS (2009) Historical perspective — Emergence of influenza A(H1N1) viruses. N Engl J Med 361: 279–85
12. Bonmarin I, Belchior E, Bergounioux J, et al (2016) Intensive care unit surveillance of influenza infection in France: the 2009/10 pandemic and the three subsequent seasons. Euro Surveill (in press)
13. Ortiz JR, Neuzil KM, Shay DK, et al (2014) The burden of influenza-associated critical illness hospitalizations. Crit Care Med 42: 2325–32
14. Streng A, Prifert C, Weissbrich B, et al (2015) Continued high incidence of children with severe influenza A(H1N1)pdm09 admitted to paediatric intensive care units in Germany during the first three post-pandemic influenza seasons, 2010/11–2012/13. BMC Infect Dis 15: 573
15. Callaghan WM, Creanga AA, Jamieson DJ (2015) Pregnancyrelated mortality resulting from influenza in the United States during the 2009–2010 pandemic. Obstet Gynecol 126: 486–90
16. Alshammari TM, AlFehaid LS, AlFraih JK, et al (2014) Health care professionals’ awareness of, knowledge about and attitude to influenza vaccination. Vaccine 32: 5957–61
17. Wicker S, Rabenau HF, von Gierke L, et al (2013) Hepatitis B and influenza vaccines: important occupational vaccines differently perceived among medical students. Vaccine 31: 5111–7
18. Catania J, Que LG, Govert JA, et al (2014) High intensive care unit admission rate for 2013–2014 influenza is associated with a low rate of vaccination. Am J Respir Crit Care Med 189: 485–7
19. Gilca R, Skowronski DM, Douville-Fradet M, et al (2015) Midseason estimates of influenza vaccine effectiveness against influenza A(H3N2) hospitalization in the elderly in Quebec, Canada, January 2015. PloS One 10:e0132195
20. Haveri A, Ikonen N, Julkunen I, et al (2015) Reduced crossprotection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine. Euro Surveill 20: 21028
21. Beigel JH (2008) Influenza. Crit Care Med 36: 2660–6
22. Bright RA, Medina MJ, Xu X, et al (2005) Incidence of adamantane resistance among influenza A(H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366: 1175–81
23. Bright RA, Shay DK, Shu B, et al (2006) Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295: 891–4
24. Hayden FG (2006) Antiviral resistance in influenza viruses-implications for management and pandemic response. N Engl J Med 354: 785–8
25. Kaiser L, Wat C, Mills T, et al (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163: 1667–72
26. Nicholson KG, Aoki FY, Osterhaus AD, et al (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355: 1845–50
27. Treanor JJ, Hayden FG, Vrooman PS, et al (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283: 1016–24
28. Hayden FG, Treanor JJ, Fritz RS, et al (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282: 1240–6
29. Walker JB, Hussey EK, Treanor JJ, et al (1997) Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. J infect Dis 176: 1417–22
30. McGeer A, Green KA, Plevneshi A, et al (2007) Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 45: 1568–75
31. Welch SC, Lam SW, Neuner EA, et al (2015) High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients. Intensive Care Med 41: 1365–6
32. Moscona A (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363–73
33. de Jong MD, Tran TT, Truong HK, et al (2005) Oseltamivir resistance during treatment of influenza A(H5N1) infection. N Engl J Med 353: 2667–72
34. Le QM, Kiso M, Someya K, et al (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108
35. Escuret V, Frobert E, Bouscambert-Duchamp M, et al (2008) Detection of human influenza A(H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 41: 25–8
36. Hoang Vu MP, Nguyen CT, Nguyen le KH, et al (2013) Oseltamivir resistance among influenza viruses: surveillance in northern Viet Nam, 2009–2012. Western Pac Surveill Response J (WPSAR) 4: 25–9
37. Dixit R, Khandaker G, Ilgoutz S, et al (2013) Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. Infect Disord Drug Targets 13: 34–45
38. Terrier O, Moules V, Carron C, et al (2012) The influenza fingerprints: NS1 and M1 proteins contribute to specific host cell ultrastructure signatures upon infection by different influenza A viruses. Virology 432: 204–18
39. Terrier O, Carron C, Cartet G, et al (2014) Ultrastructural fingerprints of avian influenza A(H7N9) virus in infected human lung cells. Virology 456–457: 39–42
40. Ehrhardt C, Seyer R, Hrincius ER, et al (2010) Interplay between influenza A virus and the innate immune signaling. Microbes Infect 12: 81–7
41. Planz O (2013) Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Res 98: 457–68
42. Zhang H, Hale BG, Xu K, et al (2013) Viral and host factors required for avian H5N1 influenza A virus replication in mammalian cells. Viruses 5: 1431–46
43. Cameron CM, Cameron MJ, Bermejo-Martin JF, et al (2008) Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets. J Virol 82: 11308–17
44. Kash JC, Basler CF, Garcia-Sastre A, et al (2004) Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus. J Virol 78: 9499–511
45. Carninci P, Yasuda J, Hayashizaki Y (2008) Multifaceted mammalian transcriptome. Curr Opin Cell Biol 20: 274–80
46. Jacquier A (2009) The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs. Nat Rev Genet 10: 833–44
47. Katagiri F, Glazebrook J (2009) Overview of mRNA expression profiling using DNA microarrays. FM Ausubel, et al (eds) Current protocols in molecular biology, chapter 22, unit 22–24
48. Nau GJ, Richmond JF, Schlesinger A, et al (2002) Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci USA 99: 1503–08
49. Feezor RJ, Oberholzer C, Baker HV, et al (2003) Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect Immunity 71: 5803–13
50. Liu R, Wang X, Chen GY, et al (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217–26
51. Kash JC (2009) Applications of high-throughput genomics to antiviral research: evasion of antiviral responses and activation of inflammation during fulminant RNA virus infection. Antiviral Res 83: 10–20
52. Reeves JD, Piefer AJ (2005) Emerging drug targets for antiretroviral therapy. Drugs 65: 1747–66
53. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369: 840–51
54. Cohen J, Vincent JL, Adhikari NK, et al (2015) Sepsis: a roadmap for future research. Lancet Infect Dis 15: 581–614
55. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1: 727–30
56. Sirota M, Dudley JT, Kim J, et al (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Translat Med 3: 96ra77
57. Josset L, Textoris J, Loriod B, et al (2010) Gene expression signature-based screening identifies new broadly effective influenza a antivirals. PloS One 5:pii:e13169
58. Terrier O, Josset L, Textoris J, et al (2011) Cellular transcriptional profiling in human lung epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-regulation of the host p53 pathway. Virol J 8: 285
59. Terrier O, Textoris J, Carron C, et al (2013) Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a. J Gen Virol 94: 985–95
60. Lamb J (2007) The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7: 54–60
61. Gilbert BE, McLeay MT (2008) MegaRibavirin aerosol for the treatment of influenza A virus infections in mice. Antiviral Res 78: 223–9
62. McClellan KJ, Wiseman LR, Wilde MI (1998) Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 12: 76–86